Cultivated seafood Market Outlook 2026–2038: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines cultivated seafood and fat, meaning fish, shellfish and animal fat grown from cells in bioreactors, sold on their own or blended with plant protein in hybrid products. It tests how fast regulatory clearances turn into products on menus and shelves, and which participants capture value among cultivated producers, food and seafood companies, investors and regulators.

Clearances have started, but sales are small. The FDA said it had no further safety questions about the cultured coho salmon of Wildtype in May 2025, after about three years and eight amendments, and cultivated seafood other than catfish needs no USDA step. Wildtype runs a pilot facility in San Francisco with capacity of 50,000 lbs of seafood a year, and a maximum of 200,000 lbs. Close to a dozen cultivated meat approvals exist worldwide and none is selling at commercial scale, according to a review published on 31 August 2026. The conclusion is that regulatory access is no longer the only gate, and cost and scale decide the next phase.

Hybrid products are the route to volume. Aleph Farms won Singapore approval on 4 August 2026 for a Cultivated Thin-Cut Steak that is blended with plant protein, and Mission Barns, whose cultivated pork fat is cleared in the United States, plans to supply business customers for use in hybrid meat. The conclusion is that a small share of cultivated cells inside a plant-based product lowers cost per kilogram and carries the flavour that plant protein lacks, so fat and hybrid formats can reach the market before whole cut products.

Capital is the constraint. Cultivated meat raised USD 74 million in 2025, a 96% fall from USD 1.8 billion in 2021, and one poultry company with US clearance has since closed. In the same period BlueNalu closed a USD 11 million round in December 2025 and is in the final stage of FDA consultation for bluefin tuna toro. The conclusion is that funding is concentrating in producers with clearances and a clear cost path, and others will consolidate or exit.

The brief treats cultivated seafood and fat as an emerging signal with a twelve year horizon to 2038. It identifies which products, regions and operators scale first and what each means for producers, food and seafood companies and investors. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Cultivated seafood is fish and shellfish grown from animal cells in bioreactors. Cultivated fat is animal fat grown the same way, mostly pork fat for use in hybrid meat.

Hybrid products blend a small share of cultivated cells with plant protein, which lowers cost and keeps flavour.

Performance depends on texture and structure, media cost, bioreactor scale and cost per kilogram.

Uses are restaurant dishes, hybrid meat and seafood products, and pet food.

The limits are low funding, the cost and scale of production, closures of early companies and differences in approval by country. The period turns on cost per kilogram and on approvals in Asia and Europe.

The cultivated seafood market, covering cultivated fish and shellfish, cultivated animal fat and hybrid products that combine cultivated cells with plant protein, and excluding cultivated meat from land animals other than fat and products made by fermentation, is valued at USD 0.01–0.03 billion in 2026 and is projected to reach USD 0.57–1.70 billion by 2038, at a CAGR of 40%.

The 2026 base rests on restaurant and pilot sales of cultivated salmon and pork fat, hybrid product launches in Singapore and early pet food sales. Growth then follows approvals in Asia and Europe, lower production cost and retail launches of hybrid products.

The forecast is sensitive to funding, cost per kilogram and approval timing. Regionally, North America leads on cleared products, Asia-Pacific on approvals and launches, and Europe on pet food registrations and review.

The base case assumes hybrid products with cultivated fat reach retail by 2030 and cost per kilogram falls enough for wider use by 2032. An accelerated case assumes quick approvals in Asia and Europe and a steep cost fall, bringing the inflection to 2030 and lifting the 2038 value to the top of the range. A delayed case assumes further funding falls and company closures, holding growth at the bottom of the range.

Growth drivers

• Regulatory clearances in the United States and Asia.
• Hybrid products with lower cost.
• Restaurant launches.
• Demand for premium seafood.

Enablers

• Strategic investors in seafood and food.
• Contract manufacturing capacity.
• Media and cell line suppliers.
• Regulatory engagement.

Restraints and barriers

• Fall in venture funding.
• Cost and scale of production.
• Closures of early companies.
• Differences in approval by country.

The direction of cultivated seafood and fat is set by pressure on wild fish supply, regulatory clearances, hybrid product design, venture funding conditions and production cost reductions.

The key participants in cultivated seafood and fat include Wildtype, Inc., BlueNalu, Inc., Mission Barns, Inc., Umami Bioworks, Hoxton Farms Ltd, Aleph Farms Ltd, Parima, Vow Group Pty Ltd, UPSIDE Foods, Inc., Eat Just, Inc., Meatly Limited, IntegriCulture Inc., Forsea Foods Ltd, Finless Foods Inc., Friends & Family Pet Food Company, Bene Meat Technologies, Thai Union Group PCL, Nissui Corporation, Cargill, Incorporated, Tyson Foods, Inc., Wageningen University & Research, Tufts University, Technion Israel Institute of Technology, National University of Singapore, U.S. Food and Drug Administration, U.S. Department of Agriculture, Singapore Food Agency, Food Standards Australia New Zealand, European Food Safety Authority, European Commission, Food Standards Agency, Federal Food Safety and Veterinary Office of Switzerland, Ministry of Health of Israel, Ministry of Health, Labour and Welfare of Japan, Ministry of Food and Drug Safety of Korea, Good Food Institute, Association for Meat, Poultry and Seafood Innovation and Cellular Agriculture Europe.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as cultivated seafood and fat mature.

Wildtype leads on cleared seafood sales, Mission Barns leads on cleared fat, and Aleph Farms and Parima lead on approvals in Singapore. Competitive intensity is low in 2026 and rises as more products clear.

Where value migrates.

In 2026 value sits with producers that hold regulatory clearances and restaurant partners, because clearance and a route to consumers are the scarce assets. By 2032 it moves toward producers that cut cost per kilogram and supply fat and cells to hybrid products at volume, because hybrid formats need small amounts of cultivated cells. By 2038 it settles in integrated cultivated ingredient platforms that supply cells, fat and seafood to food companies. Margins hold for producers with clearances in several regions and narrow for those that depend on a single restaurant channel.

The signals converge on clearances ahead of commercial scale. Close to a dozen approvals worldwide, cleared seafood and fat in the United States, hybrid products cleared in Singapore and a multi-tonne production run support growth, while falling funding, the cost and scale of production, company closures and differences in approval limit the pace.

Structural limits show where progress could slow: the fall in venture funding, cost and scale of production, closures of early companies, and differences in approval by country. The brief therefore tracks four indicators: regulatory clearances, cost per kilogram, restaurant and retail listings, and funding rounds.

Restaurants and pet food first, then hybrid products at retail, then whole cut products are the expected order of adoption.